Table
1:
Sample characteristics of infective endocarditis among COVID-19 patients
with/without non-medical opioid use.
|
|
Before Propensity Score Matching |
After Propensity Score Matching |
||||
|
|
Opioid Use |
No Use |
p-value |
Opioid Use |
No Use |
p-value |
|
|
n =32,388 |
n=1,599,127 |
|
n =32,388 |
n =32,388 |
|
|
|
n (%) |
n (%) |
|
n (%) |
n (%) |
|
|
Female |
16,643(51.4%) |
931,797 (58.3%) |
<.0001 |
16,643 (51.4%) |
16,788 (51.8%) |
0.2543 |
|
White |
23,129 (71.4%) |
988,395 (61.8%) |
<.0001 |
233,129 (74.1%) |
23,036(71.1%) |
0.4194 |
|
Black |
5,980 (18.5%) |
265,907 (16.6%) |
<.0001 |
5,980 (18.5%) |
6,161(19.0%) |
0.0684 |
|
Chronic lower RD1 |
11,254 (34.7%) |
196,455 (12.3%) |
<.0001 |
11,254 (34.7%) |
11,332 (35.0%) |
0.5202 |
|
Diabetes |
5,719 (17.7%) |
108,270 (6.8%) |
<.0001 |
5,719 (17.7%) |
5,743 (17.7%) |
0.8048 |
|
BMI |
7,973 (24.6%) |
177,554 (11.1%) |
<.0001 |
7,973 (24.6%) |
8,052 (24.9%) |
0.4719 |
|
Nicotine dependence |
18,970 (58.6%) |
139,324 (8.7%) |
<.0001 |
18,970 (58.6%) |
18,977 (58.6%) |
0.9555 |
|
SES1 |
7,844 (24.2%) |
51,559 (3.2%) |
<.0001 |
7,844 (24.2%) |
7,835(24.2%) |
0.9342 |
|
Incident IE |
580 (1.8%) |
1,503 (0.09%) |
|
580 (1.8%) |
85 (0.2%) |
|
|
|
Mean (SD) |
Mean (SD) |
|
Mean (SD) |
Mean (SD) |
|
|
Age (years) |
41.6 ± 10.9 |
38.6 ± 12.4 |
<.0001 |
41.6 ± 10.9 |
41.7 ± 10.9 |
0.6832 |
1Note acronyms: CI: confidence
Interval; IE: infective endocarditis; n: number; s: standard deviation; RD:
respiratory diseases; BMI: body mass index in kg/m2;
SES:
socioeconomic status, this variable included person’s potential health hazards
related to socioeconomic and psychosocial circumstances. The study includes data reported between 27 January
2020 and 20 January 2021.
Factors
matched were sex, race, body mass index, nicotine dependence, age, chronic
respiratory diseases, and socioeconomic status.